ArticleFrontiers in oncology2026
Case Report: Diagnosis and management of primary malignant melanoma of the bladder: a case-based review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Primary malignant melanoma of the bladder (PMMB) represents an extraordinarily rare diagnostic entity among bladder malignancies, with fewer than 50 well-documented cases reported in modern medical literature. Due to its rarity, standardized treatment protocols remain undefined, and prognostic outcomes are poorly characterized. Case presentation: A 65-year-old man presented with a primary complaint of urinary tract irritation symptoms and an occupying lesion on the bladder wall detected during an enhanced CT scan. He underwent partial cystectomy and left ureterovesical reimplantation, and pathological results confirmed the diagnosis of PMMB. The prognosis was favorable, with no recurrence observed during a 24-month follow-up. Additionally, a comprehensive literature review was conducted to elucidate the typical characteristics and current therapeutic approaches reported to date, as evidence-based guidelines have yet to be established. Conclusion: Although PMMB is a rare bladder malignancy, certain similarities in its clinical and imaging features have been observed among the reported series. This study provides an additional summary of the tumor's biological characteristics while discussing current treatment paradigms, future perspectives, and potential therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.